Epidemiology, Treatment Patterns and Survival in Canadian Patients With Chronic Hepatitis B‐Related Hepatocellular Carcinoma

• Published in: Journal of viral hepatitis 2024-11, Vol.31 (11), p.739-745
• Main Authors: Sachar, Y., Congly, S. E., Burak, K. W., Manko, A., Ko, H. H., Ramji, A., Rahman, H. S., Talia, J., Jeyaparan, J., Wong, D. W., Fung, S., Cooper, C., Kelly, E. M., Ma, M. M., Bailey, R., Minuk, G., Wong, A., Doucette, K., Elkashab, M., Sebastiani, G., Wong, P., Coffin, C. S., Brahmania, M.
• Format: Article
• Language: English
• Subjects: chronic hepatitis B; Diagnosis; Epidemiology; Fibrosis; Hepatitis B; Hepatitis B e antigen; Hepatocellular carcinoma; Liver cancer; Liver diseases; screening; Statistical analysis; Statistical models; Survival; Survival analysis; Tumors
• ISSN: 1352-0504; 1365-2893; 1365-2893
• DOI: 10.1111/jvh.13989

ABSTRACT Chronic hepatitis B (CHB) is the leading cause of hepatocellular carcinoma (HCC) globally. We described and evaluated the outcomes of patients with CHB‐HCC in Canada. In this retrospective cross‐sectional cohort study, data were analysed from CHB mono‐infected subjects seen between 1 January 2012 and 31 December 2022, and entered the Canadian Hepatitis B Network Registry. Descriptive analysis and chi‐squared modelling were used to compare cohorts, followed by multivariable survival analysis regarding survival post‐diagnosis. Statistical analyses were completed in R version 2.2. Of the 6711 patients with CHB who met inclusion criteria, 232 (3.5%) developed HCC. Compared with the CHB cohort, the majority of CHB‐HCC cohort were male, SEA and HBeAg negative and born in endemic area (80% vs. 56%, 73% vs. 55%, 84% vs. 54%, 64% vs. 40% and all p